Moreover, KROS currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we ...

Keros Therapeutics, Inc. (KROS) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session.

Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, including a potential sale of the business. To aid the decision process ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Keros Therapeutics (NASDAQ:KROS) added ~22% in the premarket on Thursday after the biotech commenced a review process to evaluate different strategic options, including a potential sale ...

$KROS insiders have traded $KROS stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales. Here’s a ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of $25.00. The company’s shares closed ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.